
CryoLife, Inc. EBITDA 2011-2026 | CRY
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA CryoLife, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 23.2 M | 35.4 M | 27.4 M | 17.7 M | 22.3 M | 11.2 M | 14.9 M | 19.7 M | 18.2 M | 16.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 35.4 M | 11.2 M | 20.7 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Delcath Systems
DCTH
|
898 K | $ 8.96 | -1.54 % | $ 321 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
FONAR Corporation
FONR
|
9.84 M | $ 18.36 | 0.11 % | $ 120 M | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
Inogen
INGN
|
-9.55 M | $ 6.35 | -1.55 % | $ 169 M | ||
|
IRadimed Corporation
IRMD
|
27.3 M | $ 100.03 | 0.84 % | $ 1.27 B | ||
|
BioSig Technologies
BSGM
|
-12.7 M | - | 37.08 % | $ 85.7 M | ||
|
LivaNova PLC
LIVN
|
228 M | $ 63.24 | - | $ 3.45 B | ||
|
Medtronic PLC
MDT
|
8.82 B | $ 86.8 | -0.42 % | $ 112 B | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
Orthofix Medical
OFIX
|
-4.11 M | $ 11.81 | -0.51 % | $ 468 M | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
IRIDEX Corporation
IRIX
|
-8.91 M | $ 1.36 | 0.93 % | $ 21.9 M | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
Penumbra
PEN
|
207 M | $ 334.96 | -0.18 % | $ 13 B | ||
|
LENSAR
LNSR
|
-7.7 M | $ 5.63 | -7.25 % | $ 64.8 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Insulet Corporation
PODD
|
564 M | $ 226.28 | -0.35 % | $ 15.9 B | ||
|
Profound Medical Corp.
PROF
|
-30.3 M | $ 5.16 | -4.44 % | $ 180 M | ||
|
AxoGen
AXGN
|
-1.19 M | $ 32.65 | 2.83 % | $ 1.5 B | ||
|
Quanterix Corporation
QTRX
|
-110 M | $ 3.74 | -5.08 % | $ 159 M | ||
|
CONMED Corporation
CNMD
|
120 M | $ 36.91 | 0.76 % | $ 1.15 B | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Electromed
ELMD
|
10.7 M | $ 24.75 | 1.04 % | $ 209 M | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
Sintx Technologies
SINT
|
-10.4 M | $ 2.57 | 0.78 % | $ 7.13 M | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
Sensus Healthcare
SRTS
|
-9.91 M | $ 4.05 | -1.46 % | $ 66.1 M | ||
|
Cytosorbents Corporation
CTSO
|
-15.2 M | $ 0.72 | 6.98 % | $ 39.2 M | ||
|
Aethlon Medical
AEMD
|
-9 M | $ 2.18 | -5.22 % | $ 3.4 M | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
Stryker Corporation
SYK
|
6.46 B | $ 328.41 | -1.26 % | $ 126 B | ||
|
AdaptHealth Corp.
AHCO
|
473 M | $ 11.56 | 11.48 % | $ 1.56 B | ||
|
Myomo
MYO
|
-13.5 M | $ 0.69 | -2.75 % | $ 28.9 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
-61 M | $ 2.35 | -3.89 % | $ 138 M | ||
|
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | ||
|
EDAP TMS S.A.
EDAP
|
-18 M | $ 3.87 | 3.75 % | $ 144 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 15.83 | -3.89 % | $ 371 M | ||
|
Outset Medical
OM
|
-62.4 M | $ 3.52 | -2.63 % | $ 53.5 K | ||
|
Inspire Medical Systems
INSP
|
64.9 M | $ 51.88 | -0.54 % | $ 1.52 B |